https://www.selleckchem.com/pr....oducts/Vorinostat-sa
67, 95% CI 0.52-0.85, P=0.001) and patients with hypopharyngeal-laryngeal carcinoma (HR 0.81, 95% CI 0.69-0.94, P=0.005). A trend towards significant interaction was found in favor of oral cavity-oropharyngeal carcinoma (P=0.161). Comparable results were observed in the pre-specified subgroup analyses. Meta-regression analyses suggested that the primary site appeared to be a predictor of survival benefits in HNSCC patients who received treatment with EGFR inhibitors over those who did not. Our meta-analysis suggests that the sur
Like
Comment
Share
